SURVYR

HIMS

Hims & Hers Health, Inc.
$29.61
+$0.41 (1.39%)Oct 21 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-73%-51%-28%-5%+17%Oct 2025Oct 2026Apr 202652w high $50.1952w low $13.74
HIMSSPY
Wall St. Highest PT $42.00 (+41.8%) Wall St. Avg PT $31.15 (+5.2%)
$15$24$33$42$51POC $29Hi $42Avg $31
Underwater Drawdown %Max DD -71.7%Current -42.3%
0.0%-71.7%
Relative Strength vs SPY-58.7% vs SPYUnderperforming
+85%0%-85%
1W
+$1.90 (6.84%)
1M
+$0.26 (0.90%)
3M
−$2.07 (6.52%)
6M
+$0.60 (2.09%)
YTD
−$2.86 (8.79%)
1Y
−$19.75 (40.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
13 analysts · mean score 2.73
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$29.61
Average target$31.15
+$1.54 (+5.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$23.00
Median$31.15
High$42.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-08-24 · Truist Securities reiterated Hold on HIMS
Reiterated
2026-08-21 · Barclays reiterated Overweight on HIMS
Reiterated
2026-08-11 · Citigroup reiterated Neutral on HIMS
Reiterated
2026-08-11 · Deutsche Bank reiterated Hold on HIMS
Reiterated
2026-08-11 · B of A Securities reiterated Neutral on HIMS
Reiterated
2026-08-11 · TD Cowen reiterated Hold on HIMS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.5B
P/E (next 12 months, estimated)37.6
52-week range$13.74 – $50.19
Revenue growth (latest quarter vs a year ago)+38.2%
Dividend yieldNo dividend
Analyst consensusHold (13)
Average analyst price target$31.15 (+5%)

What they do

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
8th percentile in sector
D-
12-1 return: -34.5%
Percentile within its GICS sector across the S&P 1500.
Growth
92nd percentile in sector
A
Revenue growth (YoY): +38.2%
Percentile within its GICS sector across the S&P 1500.
Value
10th percentile in sector
D-
Forward E/P: 2.6% · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
11th percentile in sector
D-
Profit margin: -5.5% · Return on equity: -32.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

HIMS earningsNext report in 12 days
Next report · quarter Sep 2026
Mon Nov 9, 2026After the close
EPS consensus$0.15 range -$0.05–$0.35
Revenue consensus$892.8M 13 analysts
Last 4 quarters · EPS vs estimate
Aug 10, 2026-$0.37est -$0.05−640.0%Below estimates
May 11, 2026-$0.19est $0.13−244.0%Below estimates
Feb 23, 2026$0.22est $0.19+20.8%Above estimates
Nov 3, 2025$0.28est $0.23+20.4%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 08:00:43 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.370.43
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$753.2M+38.2%
2026-03-31$608.1M–
2025-12-31$617.8M–
2025-09-30$599.0M–
2025-06-30$544.8M–

News & catalysts

More news
HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
PR Newswire · 10h ago
Noteworthy Friday Option Activity: UNH, HIMS, VEL
Nasdaq · Oct 23
HIMS 10-DAY DEADLINE ALERT: Hims & Hers Health Facing Securities Class Action Lawsuit, Investors with Losses Encouraged to Contact Hagens Berman
PR Newswire · Oct 23
HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
PR Newswire · Oct 22
INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS
PR Newswire · Oct 21
Rating changes
Reiterated
2026-08-24 · Truist Securities reiterated Hold on HIMS
Reiterated
2026-08-21 · Barclays reiterated Overweight on HIMS
Reiterated
2026-08-11 · Citigroup reiterated Neutral on HIMS
Reiterated
2026-08-11 · Deutsche Bank reiterated Hold on HIMS
Reiterated
2026-08-11 · B of A Securities reiterated Neutral on HIMS
Reiterated
2026-08-11 · TD Cowen reiterated Hold on HIMS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 08:00:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026